Related MeSH Hierarchy (4)
Chemicals and Drugs [D] » Organic Chemicals [D02] » Hydrocarbons » Hydrocarbons, Cyclic » Hydrocarbons, Aromatic » Benzene Derivatives » Phenylurea Compounds » Sorafenib
Chemicals and Drugs [D] » Heterocyclic Compounds [D03] » Acids, Heterocyclic » Nicotinic Acids » Niacinamide » Sorafenib
Chemicals and Drugs [D] » Heterocyclic Compounds [D03] » Heterocyclic Compounds, 1-Ring » Pyridines » Nicotinic Acids » Niacinamide » Sorafenib
Chemicals and Drugs [D] » Organic Chemicals [D02] » Amides » Urea » Phenylurea Compounds » Sorafenib
Description
A niacinamide and phenylurea derivative that inhibits multiple intracellular and cell surface kinases thought to be involved in ANGIOGENESIS, including RAF KINASES and VEGF RECEPTORS. It is used in the treatment of advanced RENAL CELL CARCINOMA and HEPATOCELLULAR CARCINOMA, and for treatment of THYROID CARCINOMA refractory to radioactive iodine therapy. MeSH
Hierarchy View
Phase 4 Indicated Drugs (1)
Hierarchy Tree View
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
